Andrew P. DeFilippis, MD, MSc (*); Rebekah Young, PhD (*); Christopher J. Carrubba, MD; John W. McEvoy, MB, BCh, BAO; Matthew J. Budoff, MD; Roger S. Blumenthal, MD; Richard A. Kronmal, PhD; Robyn L. McClelland, PhD; Khurram Nasir, MD, MPH; Michael J. Blaha, MD, MPH
Acknowledgment: The authors thank the other investigators, the staff, and the participants of MESA for their valuable contributions. A full list of participating MESA investigators and institutions can be found at www.mesa-nhlbi.org.
Grant Support: This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1281.
Reproducible Research Statement:Study protocol: Available at www.mesa-nhlbi.org. Statistical code: Requests will be considered by Dr. Rebekah Young on a case-by-case basis. Data set: Applications for use of MESA data are available to the public at www.mesa-nhlbi.org.
Requests for Single Reprints: Andrew P. DeFilippis, MD, MSc, University of Louisville, Division of Cardiovascular Medicine, 550 South Jackson Street, Louisville, KY 40202; e-mail, APDeFi01@louisville.edu.
Current Author Addresses: Dr. DeFilippis: University of Louisville, Division of Cardiovascular Medicine, Ambulatory Care Building, Cardiology, 550 South Jackson Street, Louisville, KY 40202.
Dr. Young: Collaborative Health Studies Coordinating Center, Building 29, Suite 210, University of Washington, Box 354922, 6200 Northeast 74th Street, Seattle, WA 98115.
Dr. Carrubba: University of Colorado, 12631 East 17th Avenue, B177, Academic Office 1, Aurora, CO 80045.
Mr. McEvoy and Dr. Blumenthal: The Johns Hopkins Hospital, Blalock 524C, 1800 Orleans Street, Baltimore, MD 21287.
Dr. Budoff: Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502.
Drs. Kronmal and McClelland: Collaborative Health Studies Coordinating Center, Building 29, Suite 210, University of Washington, Box 354922, 6200 Northeast 74th Street, Seattle, WA 98115.
Dr. Nasir: Baptist Health Medical Group, Center for Prevention and Wellness Research, 1691 Michigan Avenue, Suite 500, Miami, FL 33139.
Dr. Blaha: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Carnegie 568A, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287.
Author Contributions: Conception and design: A.P. DeFilippis, R. Young, M.J. Blaha.
Analysis and interpretation of the data: A.P. DeFilippis, R. Young, C. Carrubba, R.S. Blumenthal, R.A. Kronmal, R.L. McClelland, M.J. Blaha.
Drafting of the article: A.P. DeFilippis, R. Young, C. Carrubba, R.A. Kronmal, M.J. Blaha.
Critical revision of the article for important intellectual content: A.P. DeFilippis, R. Young, J.W. McEvoy, M.J. Budoff, R.S. Blumenthal, R.A. Kronmal, R.L. McClelland, K. Nasir, M.J. Blaha.
Final approval of the article: A.P. DeFilippis, R. Young, J.W. McEvoy, M.J. Budoff, R.S. Blumenthal, R.A. Kronmal, R.L. McClelland, K. Nasir, M.J. Blaha.
Provision of study materials or patients: M.J. Budoff.
Statistical expertise: R. Young, R.A. Kronmal, R.L. McClelland, M.J. Blaha.
Administrative, technical, or logistic support: A.P. DeFilippis, R.L. McClelland, M.J. Blaha.
Collection and assembly of data: R. Young, R.A. Kronmal, R.L. McClelland, M.J. Blaha.
Accurate risk assessment of atherosclerotic cardiovascular disease (ASCVD) is essential to effectively balance the risks and benefits of therapy for primary prevention.
To compare the calibration and discrimination of the new American Heart Association (AHA) and American College of Cardiology (ACC) ASCVD risk score with alternative risk scores and to explore preventive therapy as a cause of the reported risk overestimation using the AHA-ACC-ASCVD score.
Prospective epidemiologic study of ASCVD.
MESA (Multi-Ethnic Study of Atherosclerosis), a community-based, sex-balanced, multiethnic cohort.
4227 MESA participants aged 50 to 74 years and without diabetes at baseline.
Observed and expected events for the AHA-ACC-ASCVD score were compared with 4 commonly used risk scores—and their respective end points—in MESA after a 10.2-year follow-up.
The new AHA-ACC-ASCVD and 3 older Framingham-based risk scores overestimated cardiovascular events by 37% to 154% in men and 8% to 67% in women. Overestimation was noted throughout the continuum of risk. In contrast, the Reynolds Risk Score overestimated risk by 9% in men but underestimated risk by 21% in women. Aspirin, lipid-lowering or antihypertensive therapy, and interim revascularization did not explain the overestimation.
Comparability of MESA with target populations for primary prevention and possibility of missed events in MESA.
Of the 5 risk scores, 4, including the new AHA-ACC-ASCVD score, showed overestimation of risk (25% to 115%) in a modern, multiethnic cohort without baseline clinical ASCVD. If validated, overestimation of ASCVD risk may have substantial implications for individual patients and the health care system.
National Heart, Lung, and Blood Institute.
DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An Analysis of Calibration and Discrimination Among Multiple Cardiovascular Risk Scores in a Modern Multiethnic Cohort. Ann Intern Med. 2015;162:266–275. doi: 10.7326/M14-1281
Download citation file:
Published: Ann Intern Med. 2015;162(4):266-275.
Cardiology, Coronary Risk Factors, Prevention/Screening.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use